1. 79P Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, single-arm, phase II study. (December 2022) Authors: Wu, X.; Xia, L.; Wang, J.; Wang, C.; Zhang, Q.; Zhu, J.; Rao, Q.; Cheng, H.; Liu, Z.; Y. Yin, ; Ai, X.; Gulina, K.; Zheng, H.; Luo, X.; Chang, B.; Li, L.; Liu, H.; Li, Y.; Zhu, J. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗